1. Search Result
Search Result
Results for "

MLN

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

2

Peptides

3

Inhibitory Antibodies

2

Natural
Products

35

Recombinant Proteins

1

Isotope-Labeled Compounds

7

Antibodies

11

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15155
    MLN0905
    4 Publications Verification

    Polo-like Kinase (PLK) Cancer
    MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC50 value of 2 nM. MLN0905 can be used for the research of cancer .
    MLN0905
  • HY-123763

    CCR Inflammation/Immunology
    MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx .
    MLN3126
  • HY-19414
    MLN-4760
    15+ Cited Publications

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).
    MLN-4760
  • HY-10971
    Alisertib
    50+ Cited Publications

    MLN 8237

    Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib
  • HY-10180
    MLN8054
    5+ Cited Publications

    Aurora Kinase Cancer
    MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
    MLN8054
  • HY-RS08654

    M1; MLN; MUSER1; Linc-RAM; LINC00948

    Small Interfering RNA (siRNA) Others

    MRLN Human Pre-designed siRNA Set A contains three designed siRNAs for MRLN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MRLN Human Pre-designed siRNA Set A
    MRLN Human Pre-designed siRNA Set A
  • HY-P991360

    MLN2704 antibody

    PSMA Cancer
    MLN 591 is a human monoclonal antibody (mAb) targeting PSMA. MLN 591 can be used in Prostate cancer research .
    MLN 591
  • HY-10180R

    Reference Standards Aurora Kinase Cancer
    MLN8054 (Standard) is the analytical standard of MLN8054. This product is intended for research and analytical applications. MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
    MLN8054 (Standard)
  • HY-10180A

    Aurora Kinase Cancer
    MLN8054 sodium is an Aurora A inhibitor with radiosensitivity-enhancing activity. MLN8054 sodium can activate the DNA double-strand break reaction of prostate cancer cells in in vitro experiments. The application of MLN8054 sodium is closely related to accumulation in the G2/M phase of the cell cycle and polyploid formation. In vivo experiments show that MLN8054 sodium can significantly delay the growth of prostate cancer tumors and promote tumor cell apoptosis when used in combination with radiotherapy .
    MLN8054 sodium
  • HY-RS23083

    Small Interfering RNA (siRNA) Others

    Mln Rat Pre-designed siRNA Set A contains three designed siRNAs for Mln gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mln Rat Pre-designed siRNA Set A
    Mln Rat Pre-designed siRNA Set A
  • HY-RS08498

    Small Interfering RNA (siRNA) Others

    MLN Human Pre-designed siRNA Set A contains three designed siRNAs for MLN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MLN Human Pre-designed siRNA Set A
    MLN Human Pre-designed siRNA Set A
  • HY-15246
    Tovorafenib
    3 Publications Verification

    TAK-580; MLN 2480; BIIB-024

    Raf Cancer
    Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of pan-Raf kinase. Tovorafenib can be used for the study of glioma .
    Tovorafenib
  • HY-15473
    MLN120B
    25+ Cited Publications

    ML120B

    IKK Cancer
    MLN120B (ML120B) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .
    MLN120B
  • HY-15473A
    MLN120B dihydrochloride
    25+ Cited Publications

    ML120B dihydrochloride

    IKK Inflammation/Immunology Cancer
    MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis .
    MLN120B dihydrochloride
  • HY-100487
    TAK-243
    50+ Cited Publications

    MLN7243

    E1/E2/E3 Enzyme NF-κB Apoptosis Cancer
    TAK-243 (MLN7243) is a first-in-class, selective ubiquitin activating enzyme, UAE (UBA1) inhibitor (IC50=1 nM), which blocks ubiquitin conjugation, disrupting monoubiquitin signaling as well as global protein ubiquitination. TAK-243 (MLN7243) induces endoplasmic reticulum (ER) stress, abrogates NF-κB pathway activation and promotes apoptosis .
    TAK-243
  • HY-12285

    MLN1117; INK1117; TAK-117

    PI3K Cancer
    Serabelisib (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM.
    Serabelisib
  • HY-10453
    Ixazomib
    15+ Cited Publications

    MLN2238

    Proteasome Autophagy Cancer
    Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM).
    Ixazomib
  • HY-P99781

    MLN-1202

    CCR Inflammation/Immunology Cancer
    Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab can also improve synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Plozalizumab
  • HY-10452
    Ixazomib citrate
    5 Publications Verification

    MLN9708

    Proteasome Autophagy Cancer
    Ixazomib citrate (MLN9708) is a selective, orally active, second-generation proteasome inhibitor. Ixazomib citrate can be used for the study of a broad range of human malignancies .
    Ixazomib citrate
  • HY-10971A

    MLN 8237 sodium

    Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (MLN 8237) sodium is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib sodium induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib sodium
  • HY-123143

    MLN576

    Topoisomerase Cancer
    XR11576 (MLN576) is an orally active inhibitor of topoisomerase I and II. XR11576 shows cytotoxicity against human and murine tumor cell lines (IC50: 6-47 nM) .
    XR11576
  • HY-P99662

    MLN0264; TAK-264

    Antibody-Drug Conjugates (ADCs) Guanylate Cyclase Apoptosis Cancer
    Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis .
    Indusatumab vedotin
  • HY-P6008

    MLN peptide

    Calcium Channel Cardiovascular Disease
    Myoregulin (MLN peptide) is a member of the regulin family. Myoregulin regulates muscle performance by modulating intracellular calcium handling. Myoregulin interactes directly with sarcoplasmic reticulum Ca 2+-ATPase (SERCA) and impedinf Ca 2+ uptake into the sarcoplasmic reticulum .
    Myoregulin
  • HY-13328
    Sapanisertib
    40+ Cited Publications

    INK-128; MLN0128; TAK-228

    mTOR Autophagy Cancer
    Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
    Sapanisertib
  • HY-10484
    Pevonedistat hydrochloride
    Maximum Cited Publications
    157 Publications Verification

    MLN4924 hydrochloride

    NEDD8-activating Enzyme Apoptosis Cancer
    Pevonedistat (MLN4924) hydrochloride is a potent and selective NEDD8-activating enzyme (NAE) inhibitor, with an IC50 of 4.7 nM. Pevonedistat hydrochloride induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat hydrochloride suppresses the growth of human tumour xenografts in mice .
    Pevonedistat hydrochloride
  • HY-70062
    Pevonedistat
    Maximum Cited Publications
    157 Publications Verification

    MLN4924

    NEDD8-activating Enzyme Apoptosis Cancer
    Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM. Pevonedistat induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat suppresses the growth of human tumour xenografts in mice .
    Pevonedistat
  • HY-10453R

    MLN2238 (Standard)

    Reference Standards Proteasome Autophagy Cancer
    Ixazomib (Standard) is the analytical standard of Ixazomib. This product is intended for research and analytical applications. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM).
    Ixazomib (Standard)
  • HY-P6008A

    MLN peptide TFA

    Calcium Channel Cardiovascular Disease
    Myoregulin (MLN peptide) TFA is a member of the regulin family. Myoregulin TFA regulates muscle performance by modulating intracellular calcium handling. Myoregulin TFA interactes directly with sarcoplasmic reticulum Ca 2+-ATPase (SERCA) and impedinf Ca 2+ uptake into the sarcoplasmic reticulum .
    Myoregulin TFA
  • HY-10202A
    Tandutinib hydrochloride
    5 Publications Verification

    MLN518 hydrochloride; CT53518 hydrochloride

    FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
    Tandutinib hydrochloride
  • HY-10202
    Tandutinib
    5 Publications Verification

    MLN518; CT53518

    FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
    Tandutinib
  • HY-10202AR

    MLN518 hydrochloride (Standard); CT53518 hydrochloride (Standard)

    Reference Standards FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (hydrochloride) (Standard) is the analytical standard of Tandutinib (hydrochloride). This product is intended for research and analytical applications. Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML) . Tandutinib hydrochloride has the ability to cross the blood-brain barrier .
    Tandutinib hydrochloride (Standard)
  • HY-10202R

    MLN518 (Standard); CT53518 (Standard)

    Reference Standards FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (Standard) is the analytical standard of Tandutinib. This product is intended for research and analytical applications. Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML) . Tandutinib has the ability to cross the blood-brain barrier .
    Tandutinib (Standard)
  • HY-RS04466

    NEU; NGL; HER2; TKR1; CD340; HER-2; VSCN2; MLN 19; MLN-19; c-ERB2; c-ERB-2; HER-2/neu; p185(erbB2)

    Small Interfering RNA (siRNA) EGFR Others

    ERBB2 Human Pre-designed siRNA Set A contains three designed siRNAs for ERBB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ERBB2 Human Pre-designed siRNA Set A
    ERBB2 Human Pre-designed siRNA Set A
  • HY-RS01936

    BTZ; MLN51

    Small Interfering RNA (siRNA) Others

    CASC3 Human Pre-designed siRNA Set A contains three designed siRNAs for CASC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CASC3 Human Pre-designed siRNA Set A
    CASC3 Human Pre-designed siRNA Set A
  • HY-RS22606

    Def-4; SH3P6; LASP-1; MLN 50; Tg(Col1a1-lacZ)1Ngma

    Small Interfering RNA (siRNA) Others

    Lasp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lasp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Lasp1 Mouse Pre-designed siRNA Set A
    Lasp1 Mouse Pre-designed siRNA Set A
  • HY-RS07535

    MLN50; Lasp-1

    Small Interfering RNA (siRNA) Others

    LASP1 Human Pre-designed siRNA Set A contains three designed siRNAs for LASP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    LASP1 Human Pre-designed siRNA Set A
    LASP1 Human Pre-designed siRNA Set A
  • HY-RS13878

    CAB1; es64; MLN64

    Small Interfering RNA (siRNA) Others

    STARD3 Human Pre-designed siRNA Set A contains three designed siRNAs for STARD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    STARD3 Human Pre-designed siRNA Set A
    STARD3 Human Pre-designed siRNA Set A
  • HY-RS14973

    CART1; MLN62; RNF83

    Small Interfering RNA (siRNA) Others

    TRAF4 Human Pre-designed siRNA Set A contains three designed siRNAs for TRAF4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TRAF4 Human Pre-designed siRNA Set A
    TRAF4 Human Pre-designed siRNA Set A
  • HY-RS12373

    MLN70; S100C; HEL-S-43

    Small Interfering RNA (siRNA) Others

    S100A11 Human Pre-designed siRNA Set A contains three designed siRNAs for S100A11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    S100A11 Human Pre-designed siRNA Set A
    S100A11 Human Pre-designed siRNA Set A
  • HY-RS07469

    HB1; K81; Hb-1; KRTHB1; MLN137; MNLIX2; ghHkb1; hHAKB2-1

    Small Interfering RNA (siRNA) Others

    KRT81 Human Pre-designed siRNA Set A contains three designed siRNAs for KRT81 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KRT81 Human Pre-designed siRNA Set A
    KRT81 Human Pre-designed siRNA Set A
  • HY-19414A

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    (R)-MLN-4760, the R-enantiomer of MLN-4760, is an ACE2 inhibitor, with an IC50 of 8.4 μM. (R)-MLN-4760 is the less active isomer .
    (R)-MLN-4760
  • HY-10971R

    Aurora Kinase Autophagy Apoptosis Cancer
    Alisertib (Standard) is the analytical standard of Alisertib. This product is intended for research and analytical applications. Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC50=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity .
    Alisertib (Standard)
  • HY-13328R

    mTOR Autophagy Cancer
    Sapanisertib (Standard) is the analytical standard of Sapanisertib. This product is intended for research and analytical applications. Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
    Sapanisertib (Standard)
  • HY-W748328

    Isotope-Labeled Compounds Autophagy Proteasome Cancer
    Ixazomib- 13C2, 15N is 13C and 15N labeled Ixazomib. Ixazomib (MLN2238) is a selective, potent, and reversible proteasome inhibitor, which inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 of 3.4 nM (Ki of 0.93 nM) .
    Ixazomib-13C2,15N
  • HY-10202B

    FLT3 c-Kit PDGFR Apoptosis Cancer
    Tandutinib (MLN518) sulfate is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib sulfate can be used for acute myelogenous leukemia (AML) . Tandutinib sulfate has the ability to cross the blood-brain barrier .
    Tandutinib sulfate
  • HY-N6746

    NSC 186

    Bacterial Fungal Endogenous Metabolite Apoptosis Infection Neurological Disease Cancer
    Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
    Citrinin
  • HY-N6746R

    NSC 186 (Standard)

    Reference Standards Bacterial Fungal Endogenous Metabolite Apoptosis Infection Neurological Disease Cancer
    Citrinin (Standard) is the analytical standard of Citrinin. This product is intended for research and analytical applications. Citrinin (NSC 186) is a mycotoxin that causes food contamination and has different toxic effects. Citrinin is an effective oral anticancer agent. Citrinin has various regulatory effects on mouse immune system, including regulating the number of immune cells, inducing apoptosis and autophagy of immune cells, altering toll-like receptor expression and cytokine production. Citrinin can induce oxidative stress and lead to early apoptosis of oocytes. Low doses of Citrinin have neuroprotective effects against glutamate-induced excitotoxicity in rat cortical neurons. In addition, Citrinin also has antibacterial activity .
    Citrinin (Standard)
  • HY-156401

    PROTACs Epigenetic Reader Domain Cancer
    BRD9 c-1 (Compound 13-7) is a PROTAC BRD9 degrader . BRD9 Degrader-1 has a micromolar binding affinity for BRD9 and a nanomolar affinity for the BRD9-VCB ternary complex. BRD9 Degrader-1 induces BRD9 proteasome degradation in HEK293T cells, which can be reversed by MLN4924 (HY-70062). (Blue: VH032-cyclopropane-F (HY-125905); Black: linker (HY-W763939); Pink: HY-168695) .
    BRD9 Degrader-1
  • HY-111373
    RapaLink-1
    5+ Cited Publications

    mTOR Autophagy Cancer
    RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .
    RapaLink-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: